Inventiva (NASDAQ:IVA) Trading Up 2.7% – Still a Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price traded up 2.7% on Thursday . The stock traded as high as $3.10 and last traded at $3.06. 7,112 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 64,338 shares. The stock had previously closed at $2.98.

Analysts Set New Price Targets

IVA has been the topic of a number of recent analyst reports. Guggenheim cut their price target on shares of Inventiva from $12.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, April 4th. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of Inventiva in a research report on Friday, March 28th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.40.

Inventiva Price Performance

The firm has a 50 day moving average of $3.37 and a 200-day moving average of $2.93.

Hedge Funds Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,715 shares of the company’s stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.